Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 10/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 10/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177259 | 0.92 | IRAK4 (0.48) | CSNK1DCSNK1EIRAK4ALDH1A1 | |
| SCHEMBL29902513 | 0.90 | IRAK4 (0.47) | CSNK1DCSNK1EIRAK4GSK3BDYRK1A | |
| SCHEMBL21753560 | 0.87 | DRD2 (0.38) | CSNK1DCSNK1EKMT2AALDH1A1 | |
| SCHEMBL21753540 | 0.82 | LMNA (0.46) | KMT2AALDH1A1HPGD | |
| SCHEMBL23584998 | 0.80 | DRD2 (0.42) | CSNK1DCSNK1EPTGS1PTGS2 | |
| SCHEMBL21176835 | 0.79 | CFTR (0.40) | IRAK4ALDH1A1 | |
| SCHEMBL24292953 | 0.78 | HTR7 (0.38) | CSNK1DCSNK1EIRAK4KMT2AGSK3B | |
| SCHEMBL23160878 | 0.78 | CSNK1D (0.48) | CSNK1DCSNK1EKMT2AGSK3BBCL2L1 | |
| SCHEMBL21753533 | 0.76 | CSNK1D (0.47) | CSNK1DCSNK1EKMT2A | |
| SCHEMBL21176856 | 0.76 | IRAK4 (0.43) | IRAK4KMT2ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842425-B1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-05-22 | — | — | EP | disclosed |
| CN-110857293-B | Novel quinoline derivative inhibitor | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-09-22 | — | — | US | disclosed |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-112625027-B | Heterocyclic derivatives and use thereof | 药捷安康(南京)科技股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4036086-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2022-08-03 | — | — | EP | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| EP-3842425-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| EP-3842425-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-112625027-A | Heterocyclic derivatives and use thereof | 南京药捷安康生物科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2021057782-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021057782-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-110857293-A | Novel quinoline derivative inhibitor | 南京药捷安康生物科技有限公司 | 2020-03-03 | — | — | CN | disclosed |
| WO-2020038460-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | 南京药捷安康生物科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| WO-2020038460-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | 南京药捷安康生物科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | CSF1R, CSF3R, FLT3 | CSNK1D 462/4885CSNK1E 203/4885IRAK4 58/4885 |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | RET, MERTK, MIF | CSNK1D 676/4885CSNK1E 432/4885IRAK4 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.